Not yet in the clin­ic, Beam’s base-edit­ed, off-the-shelf CAR-T put on hold

On Fri­day, the FDA slapped a hold on Beam Ther­a­peu­tics’ pre­clin­i­cal off-the-shelf CAR-T ther­a­py, the biotech an­nounced this morn­ing.

At the end of June, the base edit­ing biotech sub­mit­ted its ap­pli­ca­tion to be­gin clin­i­cal tri­als for its CAR-T ther­a­py in pa­tients with re­lapsed/re­frac­to­ry T-cell acute lym­phoblas­tic leukemia and lym­phoma — ag­gres­sive white blood cell can­cers that do not re­spond well to treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER